McKesson Corporation, a healthcare services giant with a market cap of $97.9 billion, is set to announce its fiscal Q2 2026 results on Nov. 5. Analysts predict an adjusted EPS of $8.92, a 26.2% increase from the same quarter last year. For fiscal 2026, analysts forecast an adjusted EPS of $38.12, a 15.3% rise from fiscal 2025.

MCK stock has surged 54.9% in the past 52 weeks, surpassing the S&P 500 Index and Health Care Select Sector SPDR Fund. Despite beating Q1 2026 expectations, shares dropped 5.8% the next day due to a $189 million bad debt provision linked to Rite Aid bankruptcy.

Analysts have a bullish outlook on MCK stock, with an overall “Strong Buy” rating. Out of 17 analysts, 12 rate it as a “Strong Buy” and five as a “Hold.” The average price target is $839.27, suggesting a 6.3% upside from current levels.

Read more at Yahoo Finance: What to Expect From McKesson’s Next Quarterly Earnings Report